Hello! Today, I’m bringing some very hopeful news for the many people struggling with hair loss.
Traditional oral treatments like Finasteride or Dutasteride come with the inconvenience of daily intake and concerns over potential side effects. Recently, however, the pharmaceutical and biotech industries have cited the hair loss treatment market as the next big wave following weight-loss drugs (GLP-1), rapidly accelerating the development of innovative new medications.
Here is a summary of 3 major trendsetting hair loss treatments currently undergoing clinical trials or approaching commercialization!
1. Just a Few Shots a Year? ‘Long-Acting Injections’ 💉
Instead of taking pills every single day, development is actively underway for reformulated drugs administered via injection once every 1 to 3 months.
Mechanism: Designed to slowly release existing hair loss treatment compounds into the body over time.
Key Advantages: Significantly improves medication compliance and eliminates the hassle of daily pill consumption.
Current Status: Major domestic pharmaceutical companies (such as Daewoong Pharmaceutical and Chong Kun Dang) are smoothly advancing clinical trials for these long-acting injectable formulations.
2. Awakening Dormant Hair Follicles: Novel Mechanism Drugs (PP405, ABS-201) 🧬
Unlike traditional hormone-suppressing methods, these new-concept drugs act directly on hair follicle stem cells or target receptors to revive the natural hair growth cycle.
PP405: A drug candidate that stimulates hair follicle stem cells to transition dormant follicles back into the ‘anagen’ (growth) phase. It has drawn explosive international attention for its potential to achieve non-surgical hair regeneration and growth.
ABS-201 (Absci): An antibody treatment designed using AI technology that targets prolactin receptors (PRLR) to protect hair follicle stem cells and extend the hair growth phase. Featuring a long half-life, it is gaining high expectations for an administration schedule of just 2 to 3 doses over 6 months.
3. Topical & Scalp-Applied Treatments (Clascoterone, GT20029) 🧴
To minimize systemic side effects, targeted treatments applied directly to the scalp are also nearing the clinical finish line.
Clascoterone 5% (Cosmo): A topical androgen receptor inhibitor that locally blocks signals on the scalp. Having secured long-term Phase 3 clinical safety data, it is currently preparing for US FDA approval submission.
GT20029 (Kintor / PROTAC Technology): Utilizing targeted protein degradation technology, this topical treatment selectively destroys androgen receptors in the scalp. It demonstrated meaningful increases in hair count during Phase 2 clinical trials.
💡 Summary & Final Thoughts
Where hair loss care used to mean “taking daily pills for a lifetime,” the future of hair loss treatment is shifting toward a paradigm of “injections administered months apart,” “topical solutions minimizing side effects,” and “AI-driven biotech breakthroughs.”
The day when we can effortlessly restore full, healthy hair feels one step closer. I’ll be back with more updates as new clinical news comes out!
Leave a comment